Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Mark Z. Ma"'
Autor:
Yuyan Wang, Tyler Gable, Mark Z. Ma, David Clark, Jun Zhao, Yi Zhang, Wei Liu, Li Mao, Yuping Mei
Publikováno v:
Molecular Therapy: Nucleic Acids, Vol 6, Iss , Pp 269-278 (2017)
Lung cancer is the leading cause of cancer-related death worldwide. Although advanced drugs have benefitted patients, therapeutic success has largely been hampered because of rapid development of resistance. Here we report that PIWI-interacting RNA l
Externí odkaz:
https://doaj.org/article/9977f660727f4e638cfe88411c8c9cbb
Autor:
Mark Z. Ma, Ruxian Lin, José Carrillo, Manisha Bhutani, Ashutosh Pathak, Hening Ren, Yaokun Li, Jiuzhou Song, Li Mao
Publikováno v:
EBioMedicine, Vol 2, Iss 10, Pp 1340-1350 (2015)
Aberrant DNA methylation is a hallmark of cancer but mechanisms contributing to the abnormality remain elusive. We have previously shown that ∆DNMT3B is the predominantly expressed form of DNMT3B. In this study, we found that most of the lung cance
Externí odkaz:
https://doaj.org/article/06f71702b5c348ceae59009db2ea786a
Autor:
Hongyan Li, Zemeng Ma, Xiaoyao Hao, Xiaodong F Liu, Wenwen Dai, Yuxiang Liu, Jinyu Liu, Shukai Xia, Mark Z Ma, Mingjiu Chen, Zeyu Peng
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/532a4be423fe4ca6acb4ba21b8feb4ca
Purpose: Approximately one third of the patients with advanced non–small cell lung carcinoma (NSCLC) will initially respond to platinum-based chemotherapy, but virtually all tumors will progress (acquired resistance). The remainder will progress du
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::08b6460cbd6c18810a2601a57ad8da13
https://doi.org/10.1158/1078-0432.c.6522495.v1
https://doi.org/10.1158/1078-0432.c.6522495.v1
Supplementary Figure 2 - PDF file 693K, Notch intracellular domain IHC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::08ff5c5bec084e0ba78e7c55f665156b
https://doi.org/10.1158/1078-0432.22452492
https://doi.org/10.1158/1078-0432.22452492
Supplementary Figure Legend - PDF file 53K, legend for the supplemental figures
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::25d872cb7eddd29e83cfe2363ca9a932
https://doi.org/10.1158/1078-0432.22452489.v1
https://doi.org/10.1158/1078-0432.22452489.v1
Supplementary Figure 1 - PDF file 92K, A, Fold changes of the 84 stem-cell related genes after treated with bevacizumab + chemotherapy (Arm A) in the tumor models MDA2131-5 and MDA2131-8. The genes are arranged based on fold changes from the most dow
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ef363e6074e95d2f2c41fb365bc0db3
https://doi.org/10.1158/1078-0432.22452495
https://doi.org/10.1158/1078-0432.22452495
Autor:
Zeyu Peng, Xiaodong F. Liu, Hongyan Li, Wenwen Dai, Jinyu Liu, Xiaoyao Hao, Shukai Xia, Qun Lv, Hugh M. Davis, Mingjiu Chen, Mark Z. Ma
Publikováno v:
Cancer Research. 83:2958-2958
Introduction: While anti-PD1/PDL1 mAbs have shown success in the market only a small fraction of patients actually benefit from the therapies. Novel approaches to improve outcomes for patients who are resistant or refractory to current checkpoint inh
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f3456ca248665235d2567600959c354c
https://doi.org/10.1158/1538-7445.am2023-2958
https://doi.org/10.1158/1538-7445.am2023-2958
Autor:
Zeyu Peng, Xiaodong F. Liu, Shukai Xia, Jinyu Liu, Hongyan Li, Yuxiang Liu, Hugh M. Davis, Mingjiu Chen, Mark Z. Ma
Publikováno v:
Cancer Research. 82:5522-5522
Background: Siglec-15 is a single-pass type I membrane protein that plays an important role in the immune-suppressive tumor microenvironment (TME). Siglec-15 has low expression levels in most normal human tissues but it is highly expressed in a subse
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d05f117aaf5afb232b5cbb51fabf56b0
https://doi.org/10.1158/1538-7445.am2022-5522
https://doi.org/10.1158/1538-7445.am2022-5522
Autor:
Shukai Xia, Zeyu Peng, Xiaoyu Ding, Wanjian Gu, Yujie Zhong, Jinyu Liu, Hongyan Li, Xiaoyao Hao, Xiaodong F. Liu, Mark Z. Ma, Lan Luo, Chunni Zhang, Mingjiu Chen
Publikováno v:
Cancer Research. 82:5290-5290
Background: Trastuzumab and pertuzumab are anti-HER2 antibodies that bind to two different epitopes of HER2. Although pertuzumab itself did not exhibit substantial clinical benefit as monotherapy, it was approved to be used in combination with trastu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1b77bd5267b1e689a3268dc516ee7758
https://doi.org/10.1158/1538-7445.am2022-5290
https://doi.org/10.1158/1538-7445.am2022-5290